BERKELEY, Calif. and MAINZ, Germany — November 18, 2025 — Leads & Copy — Mainz Biomed N.V. (NASDAQ:MYNZ) has signed a Memorandum of Understanding (MOU) with OncoVanguard8 to introduce ColoAlert®, a DNA-based colorectal cancer (CRC) screening test, to South America, starting with Peru.
Colorectal cancer is a prevalent and largely preventable cancer type. In Peru, Colombia, and Ecuador, approximately 17,000 new cases are diagnosed annually, highlighting the need for early detection and preventive strategies.
The rollout of a DNA-based CRC screening solution is a significant step forward, potentially increasing screening participation, facilitating timely diagnosis, and aligning with national public health initiatives to reduce CRC-related mortality and improve population health outcomes.
The MOU outlines commercial, legal, and regulatory terms and the go-to-market strategy for the initial territory, with a final distribution agreement expected within weeks.
Mainz Biomed develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. Its flagship product, ColoAlert®, is marketed across Europe and is accurate, non-invasive, and easy to use for early detection of colorectal cancer. The Company is running its eAArly DETECT 2 clinical study to prepare for its pivotal FDA study for US regulatory approval. Mainz Biomed’s product candidate portfolio also includes PancAlert, an early-stage pancreatic cancer screening test based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in blood and stool samples.
OncoVanguard8 identifies and implements innovative healthcare solutions for Latin America, bridging the technological gap in cancer prevention and early detection. Based in Lima, Peru, the company develops strategic partnerships with insurers, hospitals, and healthcare networks to introduce advanced diagnostic technologies and promote equitable access to innovation. Operating across Peru, Colombia, and Ecuador, OncoVanguard8 serves as a regional catalyst for integrating global oncology advancements into local healthcare systems.
For media inquiries as to Mainz Biomed, contact Maximilian Schur / Simone Neeten at +49 211 529252 20 or mainzbiomed@mc-services.eu. For investor inquiries, contact ir@mainzbiomed.com.
Source: Mainz Biomed
